Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22041892 | 0.91 | RET (0.48) | RET | |
| SCHEMBL1899433 | 0.87 | RET (0.46) | RET | |
| SCHEMBL2351108 | 0.87 | RET (0.43) | RET | |
| SCHEMBL30557676 | 0.86 | RET (0.51) | RET | |
| SCHEMBL1903882 | 0.84 | RET (0.42) | RET | |
| SCHEMBL1907315 | 0.84 | RET (0.44) | RET | |
| SCHEMBL1907224 | 0.83 | MAP2K1 (0.47) | RET | |
| SCHEMBL23618974 | 0.83 | RET (0.62) | RET | |
| SCHEMBL12461307 | 0.82 | ERN1 (0.48) | RET | |
| SCHEMBL2354651 | 0.82 | RET (0.44) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | claimed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | claimed |
| US-12129266-B2 | Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2024-10-29 | — | — | US | disclosed |
| CN-111285873-B | RET inhibitor, pharmaceutical composition thereof and application thereof | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-113620945-B | RET inhibitor, pharmaceutical composition thereof and application of RET inhibitor in medicines | 广东东阳光药业股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-115605477-B | Pyrazolo [1,5-a ] pyridine derivative, preparation method, composition and application thereof | 深圳众格生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4201936-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2320907-A1 | THERAPEUTIC COMPOUNDS | Merck & Co., Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129266-B2 | Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof | RET, ROR1, BRAF | RET 1/4885 |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885 |
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | RET 79/4885 |
| US-20230322769-A1 | HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF | RET, BRAF, FGFR3 | RET 1/4885 |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NCOA4, CCDC47, CCDC6 | RET 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.